IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis

International Immunopharmacology

Volumn 9, Issue 10, 2009, Pages 1236-1243

  Irony Tur Sinai, Michal ^a   Lichtenstein, Michal ^b   Brenner, Talma ^a   Lorberboum Galski, Haya ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Apoptosis; Chimeric protein; Experimental autoimmune encephalomyelitis; Multiple sclerosis; T cells; Targeted therapy

Indexed keywords

ANNEXIN; CASPASE 3; CHIMERIC PROTEIN; DNA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; IMMUNIZATION; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE; CELL PROLIFERATION; DISEASE PROGRESSION; DNA FRAGMENTATION; DRUG DELIVERY SYSTEMS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INTERLEUKIN-2; MICE; PROTEIN ENGINEERING; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 68949173796     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.07.006     Document Type: Article

References (33)

1. Leonard W.J., Depper J.M., Crabtree G.R., Rudikoff S., Pumphrey J., Robb R.J., et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311 (1984) 626-631
2. Tsudo M., Kozak R.W., Goldman C.K., and Waldmann T.A. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A 83 (1986) 9694-9698
3. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., et al. Cloning of the gamma chain of the human IL-2 receptor. Science 257 (1992) 379-382
4. Morris J.C., and Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59 Suppl 1 (2000) i109-i114
5. Furtado G.C., Curotto de Lafaille M.A., Kutchukhidze N., and Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 196 (2002) 851-857
6. Waldmann T.A. The IL-2/IL-2 receptor system: a target for rational immune intervention. Trends Pharmacol Sci 14 (1993) 159-164
7. Chan M., and Pearson G.J. New advances in antirejection therapy. Curr Opin Cardiol 22 (2007) 117-122
8. Ramirez C.B., and Marino I.R. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 7 (2007) 137-148
9. Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27 (2007) 1-18
10. Wong B.Y., Gregory S.A., and Dang N.H. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest 25 (2007) 495-501
11. Duvic M., Cather J., Maize J., and Frankel A.E. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 58 (1998) 87-90
12. Shteingart S., Rapoport M., Grodzovski I., Sabag O., Lichtenstein M., Eavri R., et al. Therapeutic potency of il2-caspase3 targeted treatment in a murine experimental model of inflammatory bowel disease (IBD). Gut 58 (2009) 790-798
13. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7 (2007) 904-912
14. Wekerle H. Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67 Suppl 3 (2008) iii56-iii60
15. Lassmann H. Experimental models of multiple sclerosis. Rev Neurol (Paris) 163 (2007) 651-655
16. Steinman L., and Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60 (2006) 12-21
17. O'Connor K.C., Bar-Or A., and Hafler D.A. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 21 (2001) 81-92
18. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., and Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 179 (1994) 973-984
19. Irony-Tur-Sinai M., Grigoriadis N., Lourbopoulos A., Pinto-Maaravi F., Abramsky O., and Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. Exp Neurol 198 (2006) 136-144
20. Nizri E., Irony-Tur-Sinai M., Faranesh N., Lavon I., Lavi E., Weinstock M., et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203 (2008) 12-22
21. Aqeilan R., Kedar R., Ben-Yehudah A., and Lorberboum-Galski H. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. Biochem J 370 (2003) 129-140
22. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000) 455-458
23. Zhang X., Reddy J., Ochi H., Frenkel D., Kuchroo V.K., and Weiner H.L. Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 18 (2006) 495-503
24. McGeachy M.J., Stephens L.A., and Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175 (2005) 3025-3032
25. Phillips S.M., Bhopale M.K., Constantinescu C.S., Ciric B., Hilliard B., Ventura E., et al. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J Neurol Sci 263 (2007) 59-69
26. Kanwar J.R., Kanwar R.K., and Krissansen G.W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127 (2004) 1313-1331
27. Nizri E., Adani R., Meshulam H., Amitai G., and Brenner T. Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments. Neurosci Lett 376 (2005) 46-50
28. Nizri E., Irony-Tur-Sinai M., Grigoriadis N., Abramsky O., Amitai G., and Brenner T. Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development. Pharmacology 79 (2007) 42-49
29. Brenner T., Steinberger I., Soffer D., Beraud E., Ben-Nun A., and Lorberboum-Galski H. A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Immunol Lett 68 (1999) 403-410
30. Rose J.W., Lorberboum-Galski H., Fitzgerald D., McCarron R., Hill K.E., Townsend J.J., et al. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J Neuroimmunol 32 (1991) 209-217
31. Beraud E., Lorberboum-Galski H., Chan C.C., FitzGerald D., Pastan I., and Nussenblatt R.B. Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40. Cell Immunol 133 (1991) 379-389
32. Aqeilan R., Yarkoni S., and Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 457 (1999) 271-276
33. Segel M.J., Aqeilan R., Zilka K., Lorberboum-Galski H., Wallach-Dayan S.B., Conner M.W., et al. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury. Int J Exp Pathol 86 (2005) 279-288